Unibest

Pharmaceutical intermediates

Ritlecitinib tosylate Intermediates

4 pharmaceutical intermediates for Ritlecitinib tosylate. Indication: Alopecia Areata.

提交项目All intermediates

About Ritlecitinib tosylate

Originator
Fizer Inc
Indication
Alopecia Areata
Approved Date
06/23/2023
NCE Patent
06/23/2028
DS/DP
12/03/2034

Available intermediates

4 intermediates currently listed for Ritlecitinib tosylate. Request specifications, documentation or a quotation for any item below.

Ritlecitinib tosylate intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
benzyl 5-amino-2-methylpiperidine-1-carboxylate1823290-56-7//
5-AMino-2-Methyl-piperidine-1-carboxylic acid benzyl ester1207947-49-6//
benzyl(2S,5R)-5-amino-2-methylpiperidine-1-carboxylate1207853-23-3//
(R)-(-)-N-(3,5-DINITROBENZOYL)-ALPHA-PHENYLGLYCINE74927-72-3//

Other programs under R

Ramelteon RegorafenibRelugolixRemdesivir RemibrutinibRepotrectinibResmetiromRevumenib

Building toward Ritlecitinib tosylate?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →